13-05-2025
Innovations in Echocardiography, Cardiac MRI, and Genetic Testing Reshape Dilated Cardiomyopathy Treatment Landscape
Dublin, May 13, 2025 (GLOBE NEWSWIRE) -- The "Dilated Cardiomyopathy Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035" report has been added to global dilated cardiomyopathy (DCM) market is expected to grow substantially due to increasing prevalence, advancements in diagnostic technologies, and the development of novel therapeutic options. The rising burden of heart failure, aging populations, and increasing awareness about cardiovascular diseases are key drivers of this rising prevalence of cardiovascular diseases is a major driver of the dilated cardiomyopathy (DCM) market. Conditions such as heart failure, obesity, hypertension, and diabetes are on the rise globally, significantly contributing to the increasing incidence of DCM. According to the World Health Organization, heart disease remains the leading cause of death worldwide, with DCM comprising a substantial portion of heart failure cases. This growing burden is fueling demand for effective diagnostic and therapeutic advances in diagnostic technologies, including echocardiography, cardiac MRI, and genetic testing, are improving the early detection and diagnosis of DCM, enabling timely intervention and better disease management. Additionally, the development of targeted therapies based on genetic insights and personalized medicine is opening new avenues for treatment. Drugs such as beta-blockers, ACE inhibitors, ARBs, and anticoagulants are gaining traction, especially as they address the underlying mechanisms of heart ongoing advancements, the dilated cardiomyopathy (DCM) market faces several key restraints that limit its growth potential. One of the primary challenges is the limited availability of effective treatment options for advanced-stage DCM. While medications such as ACE inhibitors and beta-blockers can help manage symptoms and slow disease progression in earlier stages, treatment options for severe cases remain scarce. Heart transplantation is often the only viable solution for advanced DCM, but donor availability is low, and the procedure is costly and associated with significant medical high cost of emerging therapies including gene therapies, biologics, and transplant procedures further restricts access, particularly in low- and middle-income regions. Moreover, the expense and complexity of genetic testing for identifying familial forms of DCM create additional barriers, especially for uninsured or underinsured patients. The absence of standardized treatment protocols also complicates clinical decision-making, making it difficult for healthcare providers to consistently deliver optimal care. Additionally, current medications can produce adverse effects such as kidney dysfunction, electrolyte imbalances, and fatigue, which pose ongoing challenges in patient management and adherence. These factors collectively hinder the broader adoption and accessibility of DCM Topics Covered1. Markets Overview1.1 Introduction1.2 Market Trends1.3 Regulatory Framework1.4 Pricing Analysis1.5 Pipeline Analysis1.6 Market Dynamics1.6.1 Impact Analysis1.6.2 Market Drivers1.6.3 Market Challenges1.6.4 Market Opportunities2. Global Dilated Cardiomyopathy Market (Region), ($Million), 2023-20352.1 North America2.1.1 Key Findings2.1.2 Market Dynamics2.1.3 Market Sizing and Forecast2.1.3.1 North America Dilated Cardiomyopathy Market, by Country2.1.3.1.1 U.S.2.1.3.1.2 Canada2.2 Europe2.2.1 Key Findings2.2.2 Market Dynamics2.2.3 Market Sizing and Forecast2.2.3.1 Europe Dilated Cardiomyopathy Market, by Country2.2.3.1.1 Germany2.2.3.1.2 U.K.2.2.3.1.3 France2.2.3.1.4 Italy2.2.3.1.5 Spain2.2.3.1.6 Rest-of-Europe2.3 Asia Pacific2.3.1 Key Findings2.3.2 Market Dynamics2.3.3 Market Sizing and Forecast2.3.3.1 Asia Pacific Dilated Cardiomyopathy Market, by Country2.3.3.1.1 China2.3.3.1.2 Japan2.3.3.1.3 India2.3.3.1.4 South Korea2.3.3.1.5 Australia2.3.3.1.6 Rest-of- Asia Pacific2.4 Rest-of-the-World2.4.1 Key Findings2.4.2 Market Dynamics2.4.3 Market Sizing and Forecast3. Global Dilated Cardiomyopathy Market: Competitive Landscape and Company Profiles3.1 Key Developments3.1.1 Mergers and Acquisitions3.1.2 Synergistic Activities3.1.3 Business Expansions and Funding3.1.4 Product Launches and Approvals3.1.5 Other Activities3.2 Company Profiles3.2.1 Bristol Myers Squibb3.2.2 Cumberland Pharmaceuticals3.2.3 Berlin Cures3.2.4 AstraZeneca3.2.5 Rocket Pharmaceuticals, Inc. (Renovacor)3.2.6 Tenaya Therapeutics4. Research MethodologyFor more information about this report visit
About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data
Sign in to access your portfolio
Error in retrieving data
Error in retrieving data
Error in retrieving data
Error in retrieving data
